In certain contexts, such as ERα-negative breast tumors and advanced prostate cancer, ERβ isoforms can form heterodimers (e.g., ERβ1 with ERβ2 or ERβ5) that contribute to increased malignancy [44,45]. This evidence concerns the gene ESR2 and prostate carcinoma.